Navigation Links
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Date:5/6/2008

ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a Service Agreement with Concordia Pharmaceuticals, Inc. and initiation of preclinical studies to evaluate new applications for Salirasib using Champions Biotechnology's Biomerk Tumorgrafts(TM).

"Our Biomerk Tumorgraft preclinical platform and its benefits in drug discovery and evaluation is gaining recognition as we expand our platform to pharmaceutical and biotech companies" said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Champions is in a unique position to evaluate oncology drugs as well as novel drug combinations that may be effective in treating specific cancer types. We are pleased to be assisting Concordia Pharmaceuticals in the evaluation of new preclinical applications for Salirasib, a Ras-antagonist that acts to inhibit cancer by impairing the disease's ability to replicate defective cells."

For more information regarding Champions Biotechnology's growing business and recent news, please visit http://www.championsbiotechnology.com.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive
'/>"/>

SOURCE Champions Biotechnology
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a ... Sankyo), announced on May 22 the actions that ... past conduct under prior management ... continues to support Ranbaxy in its efforts to ... which led to the investigations by the U.S. ...
(Date:5/22/2013)... Israel , May 22, 2013  Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City.  ... 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... 22, 2013  BD (Becton, Dickinson and Company) (NYSE: ... company, announced today the publication of its 2012 ... and it continues to focus on the Company,s shared ... the principles of shared value — creating value for ... societies — are fundamental to our strategy," said ...
Breaking Medicine Technology:Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... , , SAN DIEGO, Sept. ... a leader in adult stem cell research and manufacturing, announced today ... California,s Food & Drug Branch to manufacture stem cells for human ... with California law and the applicable provisions of the Code of ...
... Conn., Aug 31 The results of the initial clinical trial ... for varicose veins, will be delivered on Wednesday, September 2, at ... Monaco. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to be Presented 2
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... of suffering, but new research indicates the combination of ... -- a smaller brain. , , Already aware that ... scientists wanted to determine if having both conditions together ... about 2 percent -- isn,t alarming, study authors said, ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in ... Nodule Center for individuals who would like to be ... cancer is the deadliest form of cancer for both men ... die from lung cancer than from breast, colon and prostate ... increases survival rates. It is well established that routine ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science Nathalie ... a recipe for making energy bars at home. , The ... takes a recipe modified from one recently featured on ... it gets more and more difficult to understand what ingredients ... of the nutrition label continues to grow and consumers are ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett ... Fairgrounds, on Friday May 10, 2013. For never having ... raising over $6,300 for cancer research. , HR ... the first $3,000 for Bronze Level Sponsorship. HR Strategies ... to match the company’s contribution of $3,000; and after ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
Breaking Medicine News(10 mins):Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... could soon be offered better treatment thanks to a new ... The University of Nottingham. A purpose-built MRI research ... diseases. The unit is based at the Queens Medical Centre ... of patients using a new, specifically-adapted MRI scanner. ...
... may yield insight into therapies for people, researchers say ... with cancer could provide crucial insight into the human ... and screening for tumors, researchers from the U.S. National ... findings appear in the Oct. 13 online journal ...
... REDONDO BEACH, Calif., Oct. 13 Function Drinks announced ... signed onto the faculty of the Hospital for Special ... as a clinical instructor and attending in spinal surgery. ... research and development for Function Drinks, a line of ...
... SPRING, Texas, Oct. 13 Go Healthy, Inc. (Pink Sheets: ... agreement with Hydro Enterprises, Inc., and Planet Green Solutions, Inc., ... that produces water from any source at a 9.5 pH ... , The ability to place the machines in bottling plants ...
... Oct. 13 Interleukin Genetics, Inc. (NYSE Amex: ILI ) ... of obesity and osteoporosis at medical meetings later this month. The ... and Nutrition Conference & Expo in Denver, Colo. , ... World Diabetes Congress - Montreal, Canada . , Date: ...
... Berger, Managing Member and Founder of Omni Management ... new office in Midtown Manhattan, located at 1120 Avenue of ... strategic geographic expansion," said Berger, "because it just makes good ... , Omni Management Group, LLC ...
Cached Medicine News:Health News:A new scan for lung diseases 2Health News:Dogs Helping to Advance Cancer Research 2Health News:Function Drinks' President & Co-Founder, Dr. Alex Hughes, Joins the Faculty of Cornell's Hospital for Special Surgery 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 3Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 2Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 3Health News:Omni Management Group Announces Opening of New York Office 2
The longer working distances achieved by the use of Galilean optics make this the perfect magnifier to enable the patient to read and write....
This full segment bifocal can be screwed into a hole in a corrective or plano lens, or mounted directly on top of a prescription lens....
An intermediate set providing a greater range of telescopes than the starter set....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Medicine Products: